Moonlight Bio
Moonlight Bio is a Seattle-based pre-clinical biotech that uses a proprietary library of evolutionary T cell mutations to engineer cell therapies for solid tumors, advancing its lead candidate toward clinical study.
- Company typePrivate
- Founded2023
- HeadquartersSeattle, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Moonlight Bio does
Moonlight Bio is a Seattle-based, privately held biotechnology company founded in 2023 that develops engineered T cell therapies for solid tumors. The company's core proposition is the systematic identification of evolutionary T cell adaptations — using a proprietary mutation library derived from human studies — to engineer cell therapies with improved function against solid tumor biology. A 2024 Nature publication co-authored by scientific founders Kole Roybal and Jaehyuk Choi of UCSF provides peer-reviewed validation of the underlying biology.
The technology platform centers on a mutation library that enables screening of T cell adaptations, with a lead cell therapy candidate advancing toward clinical study. Supporting infrastructure is built through an ecosystem of external partners: MaxCyte (electroporation/cell engineering instruments), Biocytogen (immunodeficient mouse models for in vivo efficacy), Leveragen (genetic models), Kincell Bio (manufacturing and clinical translation support), ZenQMS (quality management systems), and ScaleReady (G-Rex manufacturing platform, accessed via grant). Moonlight Bio is led by founding scientific talent from UCSF with broader team experience drawn from prior cell therapy companies including Juno and bluebird bio.
The company operates as a pre-clinical/clinical-stage biotech with no commercial product and no recurring revenue. Its capital sources include Venrock, PICI (Parker Institute for Cancer Immunotherapy), Yosemite, and individual investor Peter Fenton. The business model is typical of an early-stage cell therapy developer: invest capital to advance therapeutic candidates through preclinical and clinical milestones, with the long-term monetization path oriented toward out-licensing, partnership, or commercialization. The lead candidate is the principal near-term value driver.
Moonlight Bio firmographics
Firmographics- Name
- Moonlight Bio
- Legal name
- Moonlight Bio, Inc.
- Website
- https://moonlightbio.us
- Company type
- Private
- Founded year
- 2023
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Moonlight Bio is a Seattle-based pre-clinical biotech that uses a proprietary library of evolutionary T cell mutations to engineer cell therapies for solid tumors, advancing its lead candidate toward clinical study.
- Ownership category
- akta.pro rank
Moonlight Bio industry classification
Industry- Product category
- Cancer Immunotherapy / Cell Therapy
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- CAR-T & TCR-T Therapies (HLAAABAC)
- akta.pro secondary industry
- Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods) (HLAAABAL)
Keywords
Where Moonlight Bio is headquartered
LocationHeadquarters
- HQ city
- Seattle
- HQ country
- United States
- HQ region
- North America
Markets served
Moonlight Bio business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales
Marketing channels3 records
Moonlight Bio product offering
Product offeringCore offering
Moonlight Bio develops a proprietary suite of potency enhancement technologies that harness evolutionary T cell adaptations — naturally occurring genetic mutations identified through 'experiments of nature' in human T cells — to engineer adoptive T cell therapies targeting solid tumors. The company sequences dominant T cell clones from humans, generates libraries of diverse mutation types, screens for favorable profiles, and develops cell therapies with evolution-backed enhancement to address challenges of poor T cell proliferation, persistence, exhaustion, limited tumor infiltration, and immunosuppressive tumor microenvironment.
Product overview
Moonlight Bio is a Seattle-based biotechnology company developing a pipeline of enhanced T cell therapies for solid tumors. Its core offering consists of a proprietary suite of potency enhancement technologies that leverage naturally occurring T cell mutations identified through the study of evolutionary adaptations in human T cells. These genetic events are compiled into libraries, screened for favorable profiles, and delivered to therapeutic T cells to overcome barriers such as poor proliferation, T cell exhaustion, limited tumor infiltration, and the immunosuppressive tumor microenvironment. The company's lead cell therapy candidate is advancing toward clinical study, with support from partners including Kincell Bio, Biocytogen, Leveragen, and MaxCyte.
Differentiator
Problem solved
Functional benefit
Products and services
- Proprietary Potency Enhancement Technologies (T Cell Enhancement Platform)
Quantifiable outcome
- T cell mutations dramatically increase potency of T cells targeting a variety of tumors in model systems
Companies that use Moonlight Bio
Customer profileSegments1 record
Ideal customer profiles3 records
Moonlight Bio technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Moonlight Bio partnerships and signals
Strategic signalPartnerships
Six partnerships are on record, tiered core and minor.
- Biocytogen PharmaceuticalscoreBiocytogen Pharmaceuticals (Beijing-based, listed on SSE and HKEX) partnered with Moonlight Bio in March 2026 to develop cutting-edge cell therapies for difficult-to-treat cancers. Under the agreement, Biocytogen provides its off-the-shelf fully human antibody library against therapeutic targets, while Moonlight Bio leads preclinical development and leverages its cell therapy technologies to address solid tumor limitations. The partnership combines Biocytogen's antibody discovery platforms with Moonlight Bio's cell therapy technologies.
- ZenQMSminorZenQMS announced a collaboration with Moonlight Bio to deliver a right-sized eQMS (electronic quality management system) solution to support Moonlight Bio's operational and quality compliance needs.
- Kincell BiocoreKincell Bio announced a collaboration to advance Moonlight Bio's lead cell therapy candidate to clinical study. This collaboration supports the progression of Moonlight Bio's most advanced therapy program toward clinical investigation.
- MaxCytecoreMaxCyte, a cell-engineering company, entered into a strategic platform license (SPL) agreement with Moonlight Bio to advance T cell therapies for solid tumors. MaxCyte provides its SPL platform to support Moonlight Bio's cell engineering needs. This was announced as a new SPL client, bringing MaxCyte's total SPL agreements to 32.
- LeveragencoreLeveragen, a Boston-based biotechnology company, entered into a strategic collaboration with Moonlight Bio to advance T cell therapies using Leveragen's proprietary fully human single-domain antibody technology. Leveragen holds Japan Patent No. JP7799706 for its Singularity Platform for single-domain antibody discovery. The collaboration leverages Leveragen's antibody technology in combination with Moonlight Bio's cell therapy platforms.
- ScaleReadyminorScaleReady awarded a G-Rex Grant to Moonlight Bio. G-Rex is a proprietary bioreactor platform for cell therapy manufacturing. The grant provides Moonlight Bio with access to ScaleReady's G-Rex technology for cell therapy production.
Recent moves5 records
Expansion highlights5 records
Moonlight Bio competitors and assessment
Company assessmentDirect peers
- Cabaletta Bio: Clinical-stage cell therapy company developing engineered T cell therapies targeting cancer and autoimmune diseases. Comparable as a T cell therapy platform player working on enhanced T cell approaches.
- Sana Biotechnology: Clinical-stage cell therapy company developing engineered cell therapies for cancer and other diseases. Notably, Moonlight Bio's VP Legal Tony Parenti previously worked at Sana Biotechnology, indicating relevant talent overlap.
- Lyell Immunopharma: Clinical-stage T cell therapy company developing enhanced T cell therapies to address solid tumor challenges including exhaustion and persistence. Direct comparable on solid tumor T cell therapy platforms with proprietary enhancement strategies.
- Adaptimmune Therapeutics: Clinical-stage cell therapy company developing engineered TCR-T cell therapies for solid tumors. Highly relevant peer given shared focus on enhanced T cell potency against solid tumor indications, though with a TCR-engineering rather than mutation-enhancement approach.
- Century Therapeutics: Clinical-stage cell therapy company developing engineered T cell therapies, including approaches with enhanced potency. Notably, Moonlight Bio's CMO Nick Trede previously held roles at Century Therapeutics, indicating direct talent and technology overlap.
- Allogene Therapeutics: Clinical-stage cell therapy company developing allogeneic CAR-T therapies with next-generation approaches to overcome solid tumor limitations. Comparable to Moonlight Bio on the cell therapy modality and solid tumor focus.
- 2seventy bio: Clinical-stage cell therapy company focused on engineered T cell therapies for cancer, including next-generation approaches to overcome solid tumor barriers. Direct comparable on adoptive T cell therapy development with Moonlight Bio's approach.
Broad incumbents
- Juno Therapeutics (acquired by Bristol Myers Squibb): Pioneering CAR-T therapy company (now part of Bristol Myers Squibb) with deep expertise in engineered T cell therapies for hematological and solid tumors. Moonlight Bio's CMO previously worked at Juno, and the company serves as a benchmark for T cell therapy development and commercialization trajectories.
- Bluebird Bio: Commercial-stage gene and cell therapy company with experience in autologous engineered cell therapies. Relevant as a broader comparable in the engineered cell therapy space, particularly given the talent pedigree of Moonlight Bio's leadership team.
- Iovance Biotherapeutics: Commercial-stage cell therapy leader focused on tumor-infiltrating lymphocyte (TIL) therapies for solid tumors. Provides a reference point for cell therapy commercial economics in solid tumor indications Moonlight is targeting.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat3 records
Key risks5 records
Key highlights6 records
Customer concentration
Moonlight Bio social profiles
Digital presenceMoonlight Bio financial estimates
Financial estimateRevenue estimate
Valuation estimate
Moonlight Bio leadership team
Management profileNumber of profiles
Profiles7 records
Moonlight Bio funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Moonlight Bio M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Moonlight Bio
What does Moonlight Bio do?
Moonlight Bio develops a proprietary suite of potency enhancement technologies that harness evolutionary T cell adaptations — naturally occurring genetic mutations identified through 'experiments of nature' in human T cells — to engineer adoptive T cell therapies targeting solid tumors. The company sequences dominant T cell clones from humans, generates libraries of diverse mutation types, screens for favorable profiles, and develops cell therapies with evolution-backed enhancement to address challenges of poor T cell proliferation, persistence, exhaustion, limited tumor infiltration, and immunosuppressive tumor microenvironment.
Is Moonlight Bio a public or private company?
Moonlight Bio is a private company. It is classified as venture growth investor backed and is currently operating.
When was Moonlight Bio founded?
Moonlight Bio was founded in 2023. It employs 11 to 50 people.
Where is Moonlight Bio based?
Moonlight Bio is headquartered in Seattle, United States, in the North America region.
Who are Moonlight Bio's main competitors?
Direct peers on record are Cabaletta Bio, Sana Biotechnology, Lyell Immunopharma, Adaptimmune Therapeutics, Century Therapeutics, Allogene Therapeutics and 2seventy bio. Broad incumbents are Juno Therapeutics (acquired by Bristol Myers Squibb), Bluebird Bio and Iovance Biotherapeutics.
Does Moonlight Bio have an API?
No public API is recorded for Moonlight Bio.
What industry is Moonlight Bio in?
Moonlight Bio's product category is Cancer Immunotherapy / Cell Therapy. Its primary akta.pro industry code is HLAAABAC, CAR-T & TCR-T Therapies, with a secondary code of HLAAABAL, Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods). Its NAICS code is 541714 and its SIC code is 2836.